Loading...
•
Jun 30, 2025
Tandem Diabetes Q2 2025 Earnings Report
Tandem Diabetes Care announced its second quarter 2025 financial results, reporting record sales in the U.S. and internationally, improved gross margin, and progress in product development and commercial initiatives.
Key Takeaways
Tandem Diabetes Care achieved record second quarter sales of $240.7 million, demonstrating year-over-year and sequential gross margin improvement. The company reported a GAAP net loss of $52.4 million and a non-GAAP net loss of $32.4 million, while increasing U.S. pump shipments and advancing key product and commercial initiatives.
Achieved record second quarter sales of $240.7 million, with strong performance both in the United States and internationally.
Demonstrated significant year-over-year and sequential gross margin improvement, reaching 52% GAAP gross margin.
Initiated an early access program for the t:slim X2™ insulin pump with Control-IQ+ technology integrated with Abbott’s FreeStyle Libre® 3 Plus continuous glucose monitoring sensor in the U.S.
Received CE Mark for the Tandem Mobi insulin delivery system with Control-IQ+ technology, expanding its international market reach.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Tandem Diabetes Care expects to achieve approximately $1.0 billion in worldwide sales for the full year 2025, with an estimated GAAP gross margin of 53% to 54%. The company has revised its Adjusted EBITDA margin guidance to approximately negative 5% of sales, reflecting an acquired in-process research and development charge.
Positive Outlook
- Anticipates reaching $1.0 billion in worldwide sales for the full year 2025, a significant milestone.
- Projects U.S. sales of approximately $700 million and international sales of approximately $300 million.
- Forecasts a GAAP gross margin of approximately 53% to 54% for the full year.
- Expects increased benefit from accelerated pharmacy channel initiatives.
- Anticipates greater contributions from international sales.
Challenges Ahead
- Revised Adjusted EBITDA margin guidance to approximately negative 5% of sales for the full year.
- Adjusted EBITDA margin includes a negative 8 percentage point impact for an acquired in-process research and development charge.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...